Research article: Effects of glycyrrhizic acid on peroxisome proliferator-activated receptor gamma (PPARγ), lipoprotein lipase (LPL), SerumLipid and HOMA-IR in rats

PPAR Research

Volumn , Issue , 2010, Pages

  Yin, Chia Yoke ^a   Ha, Ton So ^a   Kadir, Khalid Abdul ^a  

^a MONASH UNIVERSITY MALAYSIA   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLUCOSE; GLYCYRRHIZIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRIACYLGLYCEROL;

ABDOMINAL WALL MUSCULATURE; ADIPOGENESIS; ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; HOMA IR; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LIPID ANALYSIS; LIPID BLOOD LEVEL; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUADRICEPS FEMORIS MUSCLE; RAT; RATING SCALE; RECEPTOR UPREGULATION; SUBCUTANEOUS FAT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 79960434600     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2010/530265     Document Type: Article

References (35)

1. R. H. Eckel, S. M. Grundy, and P. Z. Zimmet, "Themetabolic syndrome, " The Lancet, vol. 365, no. 9468, pp. 1415-1428, 2005.
2. P. J. Miranda, R. A. DeFronzo, R. M. Califf, and J. R. Guyton, "Metabolic syndrome: definition, pathophysiology and mechanisms, " American Heart Journal, pp. 33-45, 2005. (Pubitemid 40126488)
3. M. W. Schwartz and S. E. Kahn, "Insulin resistance and obesity, " Nature, vol. 402, no. 6764, pp. 860-861, 1999. (Pubitemid 129515983)
4. R. J. Mahler and M. L. Adler, "Type 2 diabetesmellitus: update on diagnosis, pathophysiology and treatment, " The Journal of Clinical Endocrinology & Metabolism, vol. 84, no. 4, pp. 1165-1171, 1999. (Pubitemid 30644370)
5. L. Guo and R. Tabrizchi, "Peroxisome proliferator-activated receptor gamma as a drug target in the pathogenesis of insulin resistance, " Pharmacology & Therapeutics, vol. 111, no. 1, pp. 145-173, 2006. (Pubitemid 43765533)
6. W. W. Harrington, C. S. Britt, J. G. Wilson, et al., "The effect of PPARα, PPARδ, PPARγ, and PPARpan agonists on body weight, body mass, and serum lipid profiles in dietinduced obese AKR/J mice, " PPAR Research, vol. 2007, Article ID 97125, 13 pages, 2007.
7. R. M. Evans, G. D. Barish, and Y. Wang, "PPARs and the complex journey to obesity, " Nature Medicine, vol. 10, no. 4, pp. 1-7, 2004.
8. J. D. Brown and J. Plutzky, "Peroxisome proliferator activated receptors as transcriptional nodal points and therapeutic targets, " Circulation, pp. 518-533, 2007. (Pubitemid 46184203)
9. I. Dahlman and P. Arner, "Obesity and polymorphisms in genes regulating human adipose tissue, " International Journal of Obesity, vol. 31, no. 11, pp. 1629-1641, 2007. (Pubitemid 350023156)
10. H. S. Camp, D. Ren, and T. Leff, "Adipogenesis and fatcell function in obesity and diabetes, " Trends in Molecular Medicine, vol. 8, no. 9, pp. 442-447, 2002. (Pubitemid 34975991)
11. R. J. Brown and D. J. Rader, "Lipases as modulators of atherosclerosis in murine models, " Current Drug Targets, vol. 8, no. 12, pp. 1307-1319, 2007.
12. Y. Zhang, J. Y. Repa, K. Gauthier, and D. J. Mangelsdorf, "Regulation of lipoprotein lipase by the oxysterol receptors, LXRα and LXRβ, " The Journal of Biological Chemistry, vol. 276, no. 46, pp. 43018-43024, 2001.
13. B. P. Kota, T. H. Huang, and B. D. Roufogalis, "An overview on biological mechanisms of PPARs, " Pharmacological Research, vol. 51, no. 2, pp. 85-94, 2004. (Pubitemid 40040538)
14. S. M. Rangwala and M. A. Lazar, "Peroxisome proliferatoractivated receptor γ in diabetes and metabolism, " Trends in Pharmacological Sciences, vol. 25, no. 6, pp. 331-336, 2004. (Pubitemid 38692426)
15. L. A. Baltina, "Chemical modification of glycyrrhizic acid as a route to new bioactive compounds for medicine, " Current Medicinal Chemistry, vol. 10, no. 2, pp. 155-171, 2003. (Pubitemid 36131651)
16. D. G. Brillante, A. J. O'sullivan, M. T. Johnstone, and L. G. Howes, "Evidence for functional expression of vascular angiotensin II type 2 receptors in patients with insulin resistance, " Diabetes, Obesity & Metabolism, vol. 10, no. 2, pp. 143-150, 2008.
17. W. T. Friedewald, R. I. Levy, and D. S. Fredrickson, "Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge, " Clinical Chemistry, vol. 18, no. 6, pp. 499-502, 1972.
18. H. Takii, T. Kometani, T. Nishimura, T. Nakae, S. Okada, and T. Fushiki, "Antidiabetic effect of glycyrrhizin in genetically diabetic KK-Ay mice, " Biological and Pharmaceutical Bulletin, vol. 24, no. 5, pp. 484-487, 2001. (Pubitemid 32499471)
19. K. Nakagawa, H. Kishida, N. Arai, T. Nishiyama, and T. Mae, "Licorice flavonoids suppress abdominal fat accumulation and increase in blood glucose level in obese diabetic KK-Ay mice, " Biological and Pharmaceutical Bulletin, vol. 27, no. 11, pp. 1775-1778, 2004. (Pubitemid 41701602)
20. R. Krätzner, F. Fröhlich, K. Lepler, et al., "A peroxisome proliferator-activated receptor γ-retinoid X receptor heterodimer physically interacts with the transcriptional activator PAX6 to inhibit glucagon gene transcription, " Molecular Pharmacology, vol. 73, no. 2, pp. 509-517, 2008. (Pubitemid 351159221)
21. H. Kageyama, T. Hirano, K. Okada, et al., "Lipoprotein lipase mRNA in white adipose tissue but not in skeletal muscle is increased by pioglitazone through PPAR-γ, " Biochemical and Biophysical Research Communications, vol. 305, no. 1, pp. 22-27, 2003. (Pubitemid 36535404)
22. O. Hanyu, T. Miida, K. Obayashi, et al., "Lipoprotein lipase (LPL) mass in preheparin serum reflects insulin sensitivity, " Atherosclerosis, vol. 174, no. 2, pp. 385-390, 2004. (Pubitemid 38597098)
23. T. M. Wallace, J. C. Levy, and D. R. Matthews, "Use and abuse of HOMA modeling, " Diabetes Care, vol. 27, no. 6, pp. 1487-1495, 2004. (Pubitemid 38680001)
24. J. P. Berger, T. E. Akiyama, and P. T. Meinke, "PPARs: therapeutic targets for metabolic disease, " Trends in Pharmacological Sciences, vol. 26, no. 5, pp. 244-251, 2005. (Pubitemid 40603072)
25. M. Berthiaume, M. Laplante, W. T. Festuccia, et al., "11beta-HSD1 inhibition improves triglyceridaemia through reduced liver VLDL secretion and partitions lipids towards oxidative tissues, " American Journal of Physiology-Endocrinology and Metabolism, vol. 293, pp. E1045-E1052, 2007. (Pubitemid 47535836)
26. S. P. J. Dullens, J. Plat, and R. P. Mensink, "Increasing apoAI production as a target for CHD risk reduction, " Nutrition, Metabolism and Cardiovascular Diseases, vol. 17, no. 8, pp. 616-628, 2007. (Pubitemid 47302308)
27. B. Desvergne and W. Wahli, "Peroxisome proliferatoractivated receptors: nuclear control of metabolism, " Endocrine Reviews, vol. 20, no. 5, pp. 649-688, 1999. (Pubitemid 30650602)
28. K. Schoonjans, J. Peinado-Onsurbe, A. M. Lefebvre, et al., "PPARα and PPARγ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene, " The European Molecular Biology Organization Journal, vol. 15, no. 19, pp. 5336-5348, 1996. (Pubitemid 26336216)
29. U. A. Boelsterli and M. Bedoucha, "Toxicological consequences of altered peroxisome proliferator-activated receptor γ (PPARγ) expression in the liver: insights from models of obesity and type 2 diabetes, " Biochemical Pharmacology, vol. 63, no. 1, pp. 1-10, 2002. (Pubitemid 34075287)
30. R. A. Memon, L. H. Tecott, K. Nonogaki, et al., "Up-regulation of peroxisome proliferator-activated receptors (PPAR-α) and PPAR-γ messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-γ-responsive adipose tissue-specific genes in the liver of obese diabetic mice, " Endocrinology, vol. 141, no. 11, pp. 4021-4031, 2000.
31. C. S. Stump, E. J. Henriksen, Y. Wei, and J. R. Sowers, "The metabolic syndrome: role of skeletal muscle metabolism, " Annals of Medicine, vol. 38, pp. 389-402, 2006. (Pubitemid 44484877)
32. B. S. Cha, T. P. Ciaraldi, L. Carter, et al., "Peroxisome proliferator-activated receptor (PPAR) γ and retinoid X receptor (RXR) agonists have complementary effects on glucose and lipid metabolism in human skeletal muscle, " Diabetologia, vol. 44, no. 4, pp. 444-452, 2001. (Pubitemid 32324355)
33. H. Wang, L. A. Knaub, D. R. Jensen, et al., "Skeletal muscle-specific deletion of lipoprotein lipase enhances insulin signaling in skeletal muscle but causes insulin resistance in liver and other tissues, " Diabetes, vol. 58, no. 1, pp. 116-124, 2009.
34. A. D. Dobrian, "The complex role of PPARγ in renal dysfunction in obesity: managing a Janus-faced receptor, " Vascular Pharmacology, vol. 45, no. 1, pp. 36-45, 2006. (Pubitemid 43996805)
35. B.H. Chung, S. W. Lim, K. O. Ahn, et al., "Protective effect of peroxisome proliferator-activated receptor gamma agonist on diabetic and non-diabetic renal diseases, " Nephrology, vol. 10, pp. 40-43, 2005.